On September 30, 2021 Immunome, Inc. (Nasdaq: IMNM), a biopharmaceutical company that utilizes its human memory B cell platform to discover and develop first-in-class antibody therapeutics, reported that it will be making an oral poster presentation on the company’s anti IL-38 antibody program at the upcoming joint meeting of the 2021 AACR (Free AACR Whitepaper)-NCI-EORTC AACR-NCI-EORTC (Free AACR-NCI-EORTC Whitepaper) International Conference on Molecular Targets and Cancer Therapeutics (EORTC-NCI-AACR) (Free ASGCT Whitepaper) (Free EORTC-NCI-AACR Whitepaper), being held October 7-10, 2021 (Press release, Immunome, SEP 30, 2021, View Source [SID1234590596]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Presentation Details:

Title: "IMM20324, a first-in-class, anti-interleukin-38 monoclonal antibody, rescues myeloid cell activation in vitro and induces robust anti-tumor responses in vivo."

Authors: John P. Dowling, et al.

Abstract Number: LBA022

Date/Time: All poster presentations are made available by the conference at the opening of the meeting on October 7, 2021, at 9:00am E.T.

On September 30, 2021 ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, reported three poster presentations at the AACR (Free AACR Whitepaper)-NCI-EORTC Virtual AACR-NCI-EORTC (Free AACR-NCI-EORTC Whitepaper) International Conference on Molecular Targets and Cancer Therapeutics (EORTC-NCI-AACR) (Free ASGCT Whitepaper) (Free EORTC-NCI-AACR Whitepaper) to be held October 7-10, 2021 (Press release, ORIC Pharmaceuticals, SEP 30, 2021, View Source [SID1234590617]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Details of the poster presentations are as follows:

Title: Initial results from a Phase 1b study of ORIC-101, a glucocorticoid receptor antagonist, in combination with enzalutamide in patients with metastatic prostate cancer
Poster #: P041

Title: Biomarker results supporting selection of RP2D from a Phase 1b study of ORIC-101, a glucocorticoid receptor antagonist, in combination with enzalutamide in patients with metastatic prostate cancer progressing on enzalutamide
Poster #: P015

Title: ORIC-114, an orally bioavailable, irreversible kinase inhibitor, has superior brain penetrant properties and enhanced potency in preclinical studies of HER2-positive breast cancer
Poster #: P234
Full abstracts and poster presentations will be available for on-demand viewing via the online platform for AACR (Free AACR Whitepaper)-NCI-EORTC on October 7, 2021, at 9 a.m. ET.

Company Webcast and Conference Call

ORIC will host a webcast and conference call to review data presented at AACR (Free AACR Whitepaper)-NCI-EORTC on Thursday, October 7, 2021, at 9:00 a.m. ET. To participate in the conference call, please dial (833) 651-0991 (domestic) or (918) 922-6080 (international) and refer to conference ID 3575856. A live webcast and audio archive of the conference call will be available through the investor section of the company’s website at www.oricpharma.com. The webcast will be available for replay for 90 days following the presentation.

On September 30, 2021 Immix Biopharma, Inc. ("ImmixBio"), a biotechnology company pioneering Tissue Specific Therapeutics (TSTx)TM for oncology and inflammation, reported that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation (ODD) to IMX-110 for the treatment of soft tissue sarcoma (Press release, Immix Biopharma, SEP 30, 2021, View Source [SID1234590560]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The FDA’s Office of Orphan Products Development grants orphan designation status to drugs and biologics that are intended for the safe and effective treatment, diagnosis or prevention of rare diseases, or conditions that affect fewer than 200,000 people in the U.S. Orphan Drug Designation provides certain benefits, including financial incentives, to support clinical development and the potential for up to 7 years of market exclusivity in the U.S. upon regulatory approval.

"We are pleased to receive FDA’s orphan drug designation in soft tissue sarcoma for IMX-110, the first clinical-stage product of our SMARxT Tissue-Specific Platform," said Ilya Rachman MD PhD, ImmixBio Founder & CEO. "We are thrilled to potentially contribute to expanding therapeutic options for oncology patients, beginning with soft tissue sarcoma."

Gabriel Morris, ImmixBio Chief Financial Officer, added: "Orphan drug designation for IMX-110 represents a substantial value creating step along our path of building a strong, independent biopharmaceutical organization."

About IMX-110

IMX-110 is a Tissue-Specific TherapeuticTM built on ImmixBio’s TME NormalizationTM Technology encapsulating a poly-kinase inhibitor and apoptosis inducer delivered deep into the tumor micro-environment, or TME. ImmixBio’s TME Normalization Technology enables IMX-110 to circulate in the bloodstream, then exit through porous tumor blood vessels, and accumulate in the TME. IMX-110 then simultaneously attacks all 3 components of the TME (cancer associated fibroblasts, or CAFs; tumor-associated macrophages/immune cells, or TAMs, and cancer itself), severing the critical lifelines between the tumor and its metabolic and structural support. IMX-110’s TME Normalization Technology causes tumor apoptosis, a non-inflammatory tumor-cell death (vs. necroptosis, which results in repeat reignition of the inflammatory cascade leading to tumor progression).

IMX-110 is currently being evaluated in a phase 1b/2a open-label, dose-escalation/dose-expansion safety, tolerability and pharmacokinetic study in patients with advanced solid tumors in the United States and Australia.

On September 30, 2021 Amplia Therapeutics Limited (ASX: ATX), ("Amplia" or the "Company"), a company developing new drugs for the treatment of cancer and fibrosis, reported that publication of a key paper from the Garvan Institute of Medical Research ("Garvan") (Press release, Amplia Therapeutics, SEP 30, 2021, View Source;[email protected] [SID1234590579]). The paper, which describes the fundamental biology underpinning Amplia’s planned Phase 2 clinical trial in pancreatic cancer patients, further highlightsthe potential benefits of using a focal adhesion kinase (FAK) inhibitor prior to administration of standard chemotherapy.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Entitled "Intravital imaging technology guides FAK-mediated priming in pancreatic cancer precision medicine according to Merlin status" the paper has been published in the high impact peer-reviewed journal Science Advances. 1 Professor Paul Timpson, a leading researcher in FAK biology at Garvan and a member of Amplia’s Scientific Advisory Board, led the research program which has shown that in mice that have been implanted with human pancreatic cancer tissue, pre-treatment with a FAK inhibitor (‘priming’) increased the responsiveness of the cancer to subsequently administered gemcitabine/Abraxane chemotherapy. Furthermore, FAK-priming reduced the metastatic spread of tumour cells to secondary sites such as the liver.

"There have been several publications over the last two years that have highlighted the potential of FAK inhibitors in pancreatic cancer, including their ability to work synergistically with chemotherapy agents" said John Lambert, CEO of Amplia: "This latest study from our collaborators at the Garvan Institute is particularly exciting as its replicates the approach that we are taking to treat first line pancreatic cancer patients in our recently announced Phase 2 clinical trial. We believe that making an established standard of care, namely chemotherapy with gemcitabine/Abraxane, more effective offers a very promising approach for improving the outcomes for these patients".

On September 30, 2021 IMV Inc. (NASDAQ: IMV; TSX: IMV), a clinical-stage biopharmaceutical company pioneering a novel class of immunotherapies against difficult-to-treat cancers, reported that two abstracts featuring two DPX-based immunotherapies have been accepted for virtual poster presentation at the upcoming AACR (Free AACR Whitepaper)-NCI-EORTC Virtual AACR-NCI-EORTC (Free AACR-NCI-EORTC Whitepaper) International Conference on Molecular Targets and Cancer Therapeutics (EORTC-NCI-AACR) (Free ASGCT Whitepaper) (Free EORTC-NCI-AACR Whitepaper) on October 7-10, 2021 (Press release, IMV, SEP 30, 2021, View Source [SID1234590597]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Poster #1:

Survivin peptides formulated in the DPX delivery platform rather than standard emulsions, elicit a robust, sustained T cell response to survivin in advanced and recurrent ovarian cancer patients.

Presenter:
Yogesh Bramhecha, Ph.D.,
Director of Translational Research, IMV Inc.

Poster Number:
LBA026

Poster #2:

DPX-SurMAGE, a novel dual-targeted immunotherapy for bladder cancer, induces target-specific T cells with a favorable safety profile in preclinical model.

Presenter:
Yves Fradet, M.D.

Professor, Department of Surgery

Faculty of Medicine, Université Laval, Quebec City

Poster Number:
LBA030

Full abstracts and e-posters will be available on demand on the conference platform on October 7, 2021 at 9am ET. Both e-posters will be available under the Scientific Publications & Posters section on IMV’s website.